Trial
NCT03756454
Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Ohio State University
Collaborators
Merck Sharp & Dohme LLC
Condition
Clostridia Difficile Colitis
Intervention
Bezlotoxumab
Why stopped
Difficulties with enrollment and inability to guarantee further study drug supply after current supply expired.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-18